Hansa Biopharma comment on today's Q1 report
Shares in Hansa Biopharma dropped around 12 percent today following the company’s release of its first quarter report showing revenue of SEK 24,2 million which was slightly below analysts’ estimates of SEK 27 million, suggesting Hansa Biopharma had one patient less during the quarter than the 6 patients expected by analysts. Upfront payments from partner Sarepta in gene therapy was SEK 9,9 million, once again showing a meaningful contribution to revenue.
Net cash by the end of the period was SEK 1.286,8 million, which was lower than analysts’ estimates, suggesting higher research and development activities as also indicated by higher operating and cash flow loss than expected. This is likely as Hansa Biopharma continues to broaden the scope and indication for the use of its imlifidase platform.
Highlights from the report:
- Positive reimbursement decision in Spain expands market access to include the five largest European markets
- Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed
- HNSA-5487: Phase 1 clinical study started in healthy volunteers
HC Andersen Capital will be hosting an event on Monday April 24th at 1:00 PM CET where Head Of Investor Relation Klaus Sindahl will comment on the report and take questions. Please use this link for participation: https://www.inderes.dk/videos/hansa-biopharma-presentation-of-q1-interim-report-2023
HC Andersen Capital receives payment from Hansa Biopharma for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 7:05 PM CET 04-20-2023.
Hansa Biopharma
Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Read more on company page